Survival estimates of this study provide a baseline for determining the incremental benefits of recently introduced systemic treatments using targeted therapy or immunotherapy for melanoma brain metastases.
According to this recent study, although combination therapy showed better efficacy than monotherapy, monotherapy (either nivolumab or ipilimumab) was safer than combination therapy as it tended to decrease the incidence of most of the treatment-related AEs.
This recent study highlights the high rate of lymphedema following inguinal lymph node dissection (ILND) for melanoma and is a potential target for future patients to be considered for immediate lymphatic reconstruction (ILR).
According to this recent study, CheckMate 238 4-year recurrence-free survivaland distant metastasis-free survival outcomes are consistent per AJCC-7 and AJCC-8 staging criteria. Outcome benefits can therefore be translated for patients diagnosed per AJCC-8.
According to this recent study, an initiative that is place-based and community driven in response to consumer demand addresses key system barriers to earlier detection of skin cancers. It is anticipated to result in flow-on reductions in skin cancer disease burden. Programme logic was useful to both describe the initiative and as a visual tool for discussions, with the potential to inform wider health service efforts to address system barriers and bottlenecks.
According to this recent study, the disease burden attributable to non-melanoma skin cancer (NMSC) will continue to increase or remain stable at high levels. Therefore, relevant policies should be developed to manage NMSC, and measures should be taken to target risk factors and high-risk groups.
This study sought to identify high-risk sentinel node (SN)-positive AJCC stage IIIA patients who are more likely to derive benefit from adjuvant systemic therapy. It concludes that patients with AJCC IIIA melanoma with SN tumor deposits ≥ 0.3 mm in maximum dimension are at higher risk of disease progression and may benefit from adjuvant systemic therapy or enrollment into a clinical trial.
According to this recent study, using dermoscopy images, readers and convolutional neural networks (CNNs) predict melanoma thickness with fair to moderate accuracy. Readers most accurately discriminated between thin (≤1.0 mm including melanoma in situ) and thick melanomas (>1.0 mm).
According to this recent study, circulating tumour cells (CTCs) are a unique potential tool for pharmacogenomic studies to guide treatment strategies in advanced disease.
It is essential that interdisciplinary teams better understand radiation therapy (RT) modalities, benefits, and drawbacks. This review will provide the role and indications for RT in patients with non-melanoma skin cancer.